DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Sickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study Finds
Intensifying treatment with hydroxyurea in young children with sickle cell anemia is safe and improves several disease parameters in the long run, researchers demonstrated in a clinical trial (NCT00305175) comparing toddlers with older children.
Based on the positive findings, researchers argue that the practice of giving small children higher doses of the drug needs to be further studied. A new clinical trial (NCT03020615) addressing these matters is in the planning stage.
The study, “Hydroxyurea at Maximal Tolerated Dose (MTD) Prior to Completion of the β-Globin Switch Has Additive but Not Sustained Benefits in Fetal Hemoglobin Production,” was presented at the ASH 2016 Annual Meeting.
+myBinderRelated Content
-
education & researchSocial-Environmental Factors and Cognitive and Behavioral Functioning in Pediatric Sickle Cell DiseaseSickle cell disease (SCD), an inherited ...
-
education & researchEXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea...Background: Cerebral vasculopathy in s...
-
news & eventsSCDAA Statement About Gene Therapy ApprovalOn Dec. 8, 2023, the Food and Drug Admin...
-
news & eventsInvestigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical TrialImara’s investigational oral inhibitor...
-
videos & visualsInfographic: Understanding Sickle Cell Disease – ASHhttps://www.onescdvoice.com/wp-content/u...
-
news & eventsSickle Cell Disease Association of America, Inc. and Hemanext® Inc. Form New Strategic PartnershipSickle Cell Disease Association of Ameri...
-
videos & visualsAlabama Man Free of Sickle Cell After Gene Therapyhttps://www.youtube.com/watch?v=E9vYON8D...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.